Pharma CEO
Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy
SG Tylor
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...